stockrow
Sunday 8 November 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
28.53
0.65
+2.33%
Follow PBLS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 5 | 7 | +142.8% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (118) | (146) | (171) | +23.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (118) | (146) | (171) | +23.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (83.48) | (92.40) | (83.02) | +10.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (53.57) | (61.15) | (4.08) | +14.2% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.45) | (0.15) | (0.04) | (66.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (54.02) | (61.30) | (4.12) | +13.5% | ||||||
| Book value | — | — | — | — | — | — | — | — | (198.49) | (8.17) | 36.24 | (95.9%) | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 2 | 9 | +4.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (104) | (124) | (118) | +19.4% | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | (1) | (65.2%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (104) | (124) | (119) | +18.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 60 | (27) | 1,063 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (71) | (13) | (1,114) | (81.3%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (384) | (17) | 1,048 | (95.7%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (162.50) | 0.00 | (162.5) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 41.06 | 0.00 | +41.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 145 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Latest quarter Jun 2026 · fundamentals updated 2 Nov 2026
Parabilis Medicines, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics Inc. | $3.6B | — (loss-making) | — (loss-making) | −76.29% (below 0%: shrinking) | n/m | +151.98% (above 0%: growing) | 100.00% | (1,550.05%) | Compare |
| TNGX Tango Therapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IOVA Iovance Biotherapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | +80.07% (above 0%: growing) | n/m | +89.72% (above 0%: growing) | 0.00% | (19.73%) | Compare |
| IRON Disc Medicine, Inc. | $3.5B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PBLS Parabilis Medicines, Inc. | $3.4B | — (loss-making) | — | — | n/m | — | 100.00% | (34,382.43%) | |
| ARQT Arcutis Biotherapeutics, Inc. | $3.4B | 112× | 64.7× | +45.05% (above 0%: growing) | +12.00% (above 0%: growing) | +1,171.89% (above 0%: growing) | 91.34% | 6.56% | Compare |
| TARS Tarsus Pharmaceuticals, Inc. | $3.3B | — (loss-making) | — (loss-making) | +63.92% (above 0%: growing) | n/m | −144.14% (below 0%: shrinking) | 92.86% | (340.29%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −47.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELVN Enliven Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.4B | — | — | +45.05% | — | +1.62% | 0.00% | 0.00% |